Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 5:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,299 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pediatric Cancer Clear all
Recruiting No phase listed Observational

LIFE Cancer Survivorship Database for Pediatric Cancer

NCT01518400
View directory record Official record
Conditions
Pediatric Cancer
Interventions
Not listed
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
Not listed
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2050
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 16, 2026, 5:26 PM EDT
Not listed Phase 1Phase 2 Interventional

Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML

NCT03825367
View directory record Official record
Conditions
AML, Childhood
Interventions
Nivolumab, 5-azacytidine
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 30 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
12
States / cities
Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 16, 2026, 5:26 PM EDT
Completed Not applicable Interventional

Survivor-Sleep Health Information Program

NCT04863157
View directory record Official record
Conditions
Sleep Problem, Insomnia, Pediatric Cancer
Interventions
Survivor-SHIP
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
5 Years to 12 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Oct 16, 2026, 5:26 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1

NCT04954001
View directory record Official record
Conditions
Neurofibromatosis 1, Plexiform Neurofibroma, NF1
Interventions
FCN-159
Drug
Lead sponsor
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Industry
Eligibility
2 Years to 70 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
5
States / cities
Los Angeles, California • Gainesville, Florida • St. Petersburg, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 16, 2026, 5:26 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Metastatic Cancer

NCT00020267
View directory record Official record
Conditions
Lung Cancer, Adult Soft Tissue Sarcoma, Colorectal Cancer, Bone Cancer, Ovarian Sarcoma, Melanoma, Colon Cancer, Rectal Cancer, Breast Cancer, Eye Cancer, Uterine Sarcoma
Interventions
interleukin-2, MAGE-12 peptide vaccine, Montanide ISA-51
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Timeline
Started 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 16, 2026, 5:26 PM EDT
Enrolling by invitation Not applicable Interventional

VR-PAT During Home Burn Dressings - Multisite

NCT05673551
View directory record Official record
Conditions
Burns, Acute Pain, Procedural Pain, Injuries, Pediatric ALL
Interventions
VR-PAT
Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Columbus, Ohio • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 16, 2026, 5:26 PM EDT
Completed No phase listed Observational

Checking Out Checking In: The Development and Validation of an Electronic Screening Tool for Pediatric Psychosocial Distress

NCT02423031
View directory record Official record
Conditions
Cancer
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
8 Years to 21 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
4
States / cities
Aurora, Colorado • Baltimore, Maryland • Bethesda, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 16, 2026, 5:26 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

NCT04775485
View directory record Official record
Conditions
Low-grade Glioma, Advanced Solid Tumor
Interventions
Tovorafenib
Drug
Lead sponsor
Day One Biopharmaceuticals, Inc.
Industry
Eligibility
6 Months to 25 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
14
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Oct 16, 2026, 5:26 PM EDT
Recruiting Early Phase 1 Interventional

Indocyanine Green (ICG) Guided Sentinel Lymph Node Mapping for Pediatric Visceral Solid Tumors

NCT05645523
View directory record Official record
Conditions
Solid Tumor
Interventions
Indocyanine Green
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 20 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Chicago, Illinois • Pittsburgh, Pennsylvania • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 16, 2026, 5:26 PM EDT
Completed Not applicable Interventional

Parent Educational Discharge Support Strategies

NCT03227068
View directory record Official record
Conditions
Educational Activities
Interventions
PEDSS - symptom management, PEDSS - support for the caregiver
Other
Lead sponsor
Duke University
Other
Eligibility
3 Years to 17 Years
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
15
States / cities
Miami, Florida • Chicago, Illinois • Winfield, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Oct 16, 2026, 5:26 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Estimating the Global Need for Palliative Care for Children

NCT02553148
View directory record Official record
Conditions
Cancer, Congenital Anomalies, Cardiovascular Disease, HIV
Interventions
Need for children's palliative care
Other
Lead sponsor
International Children's Palliative Care Network
Other
Eligibility
Up to 19 Years
Enrollment
18,837,613 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Fairfax Station, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Oct 16, 2026, 5:26 PM EDT
Active, not recruiting Not applicable Interventional

NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors

NCT04656496
View directory record Official record
Conditions
Obesity, Childhood, Cancer, Survivorship
Interventions
NOURISH-T+, Brief NOURISH-T+
Behavioral
Lead sponsor
University of South Florida
Other
Eligibility
5 Years to 14 Years
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
10
States / cities
Washington D.C., District of Columbia • Gainesville, Florida • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 16, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Results available

Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation

NCT02458235
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphoid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome
Interventions
azacitidine, donor lymphocyte infusion
Drug · Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 29 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 12, 2020 · Synced Oct 16, 2026, 5:26 PM EDT
Recruiting Phase 1 Interventional

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

NCT04485559
View directory record Official record
Conditions
Recurrent World Health Organization (WHO) Grade II Glioma, Low-grade Glioma, High-Grade Glioma (HGG)
Interventions
Everolimus, Trametinib
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Year to 25 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 16, 2026, 5:26 PM EDT
Not listed No phase listed Observational

Biomarker Verification in Pediatric Chronic GvHD: ABLE 2.0 / PTCTC GVH 1901 Study

NCT04372524
View directory record Official record
Conditions
Chronic Graft-versus-Host-Disease, Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation, Blood Cancer, Non-Malignant Hematologic and Lymphocytic Disorder
Interventions
Not listed
Lead sponsor
University of British Columbia
Other
Eligibility
0 Years to 24 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
11
States / cities
San Francisco, California • Denver, Colorado • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 16, 2026, 5:26 PM EDT
Completed Not applicable Interventional

Registry and Screening Tool to Identify Children With Asthma Likely to Benefit From Home Assessment and Remediation

NCT03916237
View directory record Official record
Conditions
Asthma, Pediatric ALL, School Health Services, Registries, Medical Informatics, Home Visits, Housing Problems, Social Determinants of Health, Healthcare Disparity, Health Status Disparity
Interventions
Home assessment, Home remediation, Referral to Medical Legal Partnership, Regular School Based Health Asthma Care
Other
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
5 Years to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 19, 2023 · Synced Oct 16, 2026, 5:26 PM EDT
Completed No phase listed Observational

Accuracy Performance Verification of the INVOS™ System in Pediatrics

NCT05962905
View directory record Official record
Conditions
Cerebral Oxygenation, Pediatric ALL
Interventions
Blood sample, INVOS monitoring
Other · Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
0 Years to 21 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
Kansas City, Missouri • St Louis, Missouri • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 16, 2026, 5:26 PM EDT
Completed Phase 1 Interventional

A Phase I Study of SU101 in Pediatric Patients With Refractory Malignancy

NCT00001573
View directory record Official record
Conditions
Glioma, Sarcoma
Interventions
SU101
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 16, 2026, 5:26 PM EDT
Terminated Phase 1 Interventional

SU5416 in Treating Children With Recurrent or Progressive Brain Tumors

NCT00006247
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
semaxanib
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
Up to 21 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
9
States / cities
San Francisco, California • Washington D.C., District of Columbia • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2009 · Synced Oct 16, 2026, 5:26 PM EDT
Active, not recruiting No phase listed Observational

Next Generation Pathogen Sequencing for Prediction of Adverse Events

NCT03226158
View directory record Official record
Conditions
Bloodstream Infection
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 24 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 16, 2026, 5:26 PM EDT
Completed No phase listed Observational Results available

Home or Away From Home - Descriptive Interviews (Aim 2)

NCT02794207
View directory record Official record
Conditions
Pediatric Acute Myeloid Leukemia
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years to 22 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
11
States / cities
Little Rock, Arkansas • Palo Alto, California • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 16, 2026, 5:26 PM EDT
Completed Not applicable Interventional Results available

Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults With Chronic Conditions

NCT03938324
View directory record Official record
Conditions
Sickle Cell Disease, Chronic Kidney Diseases, Systemic Lupus Erythematosus, Childhood Cancer, Inflammatory Bowel Diseases, Stem Cell Transplant, Organ Transplant, Diabetes Mellitus, Type 1, Cystic Fibrosis
Interventions
PiCASO Intervention Group, Sham Comparator: Attention Control Group
Behavioral
Lead sponsor
Duke University
Other
Eligibility
16 Years to 22 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 16, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Results available

Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma

NCT00027846
View directory record Official record
Conditions
Brain Tumor, Central Nervous System Tumor
Interventions
filgrastim, carboplatin, cyclophosphamide, etoposide, vincristine sulfate, radiation therapy, Mesna, therapeutic conventional surgery
Biological · Drug · Radiation + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
140
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 118 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 16, 2026, 5:26 PM EDT
Withdrawn Phase 2 Interventional

Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Pediatric Patients Undergoing Single or Double Umbilical Cord Blood Transplantation

NCT01554254
View directory record Official record
Conditions
Cord Blood Transplant, Hematologic Malignancy, Inherited Metabolic Disease
Interventions
TXA127
Drug
Lead sponsor
Tarix Pharmaceuticals
Industry
Eligibility
6 Months to 20 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 31, 2016 · Synced Oct 16, 2026, 5:26 PM EDT